Prognostic significance of myeloid-derived suppressor cells and systemic inflammation in newly diagnosed diffuse large B cell lymphoma treated with chemoimmunotherapy.

The revised International Prognostic Index (R-IPI) is an important prognostic tool in diffuse large B cell lymphoma (DLBCL); however, outcomes can vary markedly within R-IPI groups, and additional prognostic markers are needed. We conducted a prospective observational study to evaluate the circulating immature myeloid (IM) cell subsets and cytokine profiles of 31 patients with newly diagnosed DLBCL before and after chemoimmunotherapy. Among circulating IM cells, myeloid-derived suppressor cells (MDSCs) were the predominant cell type (73.8% ± 26%). At baseline, circulating monocytic MDSCs (M-MDSCs) and polymorphonuclear MDSCs (PMN-MDSCs) were predominantly mutually exclusive. Patients with DLBCL clustered into three distinct immunotypes according to MDSC levels and subtype predominance: M-MDSC

Informations de copyright

Copyright © 2023 ISEH -- Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of Interest Disclosure DMF has received research funding from TeneoBio and Celgene and honoraria from Cytognos. BH is an advisory board member for BeiGene, ADC Therapeutics, and Morphosys. TM has received consulting fees from Kite Pharma. RJ has received consulting fees from AbbVie, AstraZeneca, BeiGene, Genentech, Janssen, Loxo/Lilly, Morphosys, Pharmacyclics, and TG Therapeutics; has served on the speaker's bureau for AbbVie, Adaptive Biotech, AstraZeneca, BeiGene, Janssen, Loxo/Lilly, Pharmacyclics, and TG Therapeutics; and has received research funding from TG Therapeutics, AstraZeneca, Loxo/Lilly, and AbbVie. NG reports serving as a consultant or advisor for Seattle Genetics, TG Therapeutics, AstraZeneca, Pharmacyclics/Janssen, Bristol-Myers Squibb, Gilead Sciences, BeiGene, Incyte, Karyopharm, Roche/Genentech, Novartis, Loxo/Lilly, Genmab, Adaptive Biotechnologies, Syncopation, and Lava Therapeutics; participation on speakers bureau for Kite/Gilead, AstraZeneca, Bristol-Myers Squibb, Pharmacyclics/Janssen, and Epizyme; research funding from Pharmacyclics, TG Therapeutics, Genentech/Roche, Bristol-Myers Squibb/Celgene, Gilead Sciences, Morphosys, and AbbVie. The other authors do not have any conflicts of interest to declare in relation to this work.